0.46Open0.30Pre Close41 Volume1.06K Open Interest40.00Strike Price1.67KTurnover79.67%IV11.83%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.1935Delta0.0698Gamma90.43Leverage Ratio-0.0804Theta0.0012Rho17.50Eff Leverage0.0135Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet